Overlooked AspartameInduced Hypertension
To the Editor: As a constructive comment on the excellent article by Trewet and Ernst 1 on "resistant hypertension," allow me to mention an important factor contributing to hypertension that continues to be overlooked: "diet" products containing aspartame which are being consumed by an estimated twothirds of the population.
I reported earlier on hypertension in 64 aspartame reactors who were not known to have had an elevated blood pressure prior to using this chemical. 2 Its severity was impressive-eg, a registered nurse with readings as high as 280/160. The blood pressure in another nurse rose to 240/150. Several patients were studied to rule out pheochromocytoma. The causative role of aspartame products was indicated by 1) the striking improvement or normalization of blood pressure after stopping aspartame, and 2) the prompt recurrence of hypertension following aspartame resumption.
The association of hypertension with the consumption of cola beverages (Diet Coke TM , Diet Pepsi TM ) has been confirmed by Winkelmayer et al 3 in a large prospective study of female nurses-but NOT with caffeine consumption. They speculated that "perhaps some other compound contained in soda-type soft drinks . . . may be responsible for the increased risk of hypertension."
I have reviewed the likely pharmacologic basis, especially the conversion of phenylalanine (comprising half of the aspartame molecule) to dopamine, epinephrine, and norepinephrine . . . all pressor substances. 2 Other aspartame reactors have evidenced peripheral vasomotor features (including the Raynaud phenomenon), 2 and probable pulmonary hypertension.
Serious Cardioembolic Stroke Resulting from an Overlooked Left Ventricular Noncompaction
To the Editor: Left ventricular hypertrabeculation/noncompaction (LVHT) is a rare congenital cardiomyopathy that remains frequently overlooked and is known to have an increased tendency to lead to thromboembolic events. 1 Because of the serious potential for cardiovascular complications, early recognition is essential. We report the case of a 14-year-old boy with Down syndrome who developed an acute cardioembolic stroke during hospital admission for heart failure. Three years previously, he had undergone surgical repair of a ventricular septal defect (perimembranous type), and a permanent pacemaker was implanted due to complete atrioventricular block after repair. During follow up, progression of aortic regurgitation was noted; the left ventricular cavity had become dilated and systolic function had worsened.
Recently, the patient was admitted due to dyspnea on exertion (New York Heart Association functional class III). On physical examination, he had a diastolic murmur in the left parasternal area (grade IV/VI). On the tenth hospital day, he developed an acute left-sided hemiparesis. Computed tomography and angiography of the brain demonstrated occluded right middle cerebral artery (MCA) with hyperacute infarct along the right MCA territory. Transthoracic echocardiogram demonstrated a markedly dilated left ventricle (LV) with severely impaired systolic function (LV end diastolic diameter 83 mm; LV ejection fraction 20%). His aortic valve had severe aortic regurgitation due to malcoaptation between the noncoronary and right coronary cusp. Also, there was a spongy-like subendocardial layer with prominent trabeculation, suggestive of LVHT (Fig.) . Intracardiac thrombus was not detected. The preoperative transthoracic echocardiogram performed three years previously was retrospectively reviewed and LVHT was noted. The LV systolic function and cavity size were normal. This case report shows that physicians and echocardiographers must be aware of LVHT in order to prevent any delay in diagnosis.
Because of the serious potential for cardiovascular complications, early recognition is essential.
2 Prophylactic anticoagulation should be considered to prevent embolic stroke when the ventricular systolic function has begun to deteriorate. 3 
The Nose Knows Cancer Recurrence
To the Editor: Diffuse large B-cell lymphoma (DLBCL) is a rapidly proliferating neoplasm that presents with rapid nodal growth, weight loss, fever, night sweats, or fatigue.
1 Untreated, DLBCL causes significant morbidity, and ultimately, death. Fortunately, this disease is responsive to chemotherapy and the monoclonal antibody rituximab. We report on a noncompliant patient with DL-BCL of the neck whose disease activity was indicated by waxing and waning malodorous, necrotic tumor tissue.
A 25-year-old female was diagnosed with DLBCL involving bilateral neck nodes. Computed tomography and positron emission tomography showed disease limited to the neck; bone marrow biopsy was normal. Cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab (CHOP-R) were administered with significant decrease in adenopathy. However, the patient failed to complete the prescribed six cycles, and despite regular attempts to urge the patient to continue treatment, she declined further chemotherapy. After several weeks, however, the neck nodes became markedly enlarged and necrotic with malodorous discharge; this prompted medical attention. The patient received further chemotherapy (ifosfamide, carboplatin, etoposide, and rituximab), and after each cycle, there was dramatic tumor shrinkage, wound closure, and odor resolution. The patient repeatedly failed to follow up at suggested intervals for treatment. Several times, however, the patient presented to the emergency department prompted by fungating, open tumor wounds with an overpowering putrid odor that impeded her quality of life. Each time chemotherapy was administered, the odor abated, but she ceased follow up since the smell was not interfering with her personal life. Most recently, after three cycles of chemotherapy at regular intervals, the wounds closed, the nodes diminished, and the foul odor resolved. Despite this favorable response, the patient again failed to comply with chemotherapy and again called the clinic once the odor and symptoms returned.
Rapidly growing neoplasms may rarely form chronic, foul-smelling, draining wounds that impede quality of life and cause social isolation. 2, 3 Clinicians typically monitor disease response to antineoplastic therapy with radiographic or nuclear medicine studies. However, recognizing unusual cancer-associated complaints such as ethanol-induced node pain, chin numbness, or intertreatment necrotic tumor odor may provide the physician with simple clues to treatment response that may signal ongoing or recurrent malignancy. 4 As Osler eloquently stated: "Learn to see, learn to hear, learn to smell. Know that by practice alone you can become an expert." of HPO is not completely understood, but the presence of arteriovenous shunts (either in the heart or in the lungs) seems to be condicio sine qua non. We support this hypothesis by describing a patient with nonsmall cell lung cancer who had HPO at the time of diagnosis, but not at the time of extrapulmonary relapse.
HPO may be found in a number of medical conditions, including lung cancer or lung metastases, congenital cyanotic heart disease, liver cirrhosis, and other systemic illnesses with pulmonary involvement.
1-3 HPO regresses with effective treatment of the malignancy. 1 Symptomatic treatment may include the use of nonsteroidal anti-inflammatory drugs, bisphosphonates, or octreotide.
A 71-year-old female was diagnosed with nonsmall cell lung cancer (NSCLC) stage IIIA. She underwent a whole body bone scan, which was compatible with HPO. The patient was treated with platinum-based chemotherapy, radiation to the right chest and mediastinum, and had a right lower lobectomy and right upper lobe wedge resection. Six months later, she developed metastatic lesions in the brain confirmed by magnetic resonance imaging. Computed tomography scans of her chest, abdomen, and pelvis were negative. Her bone scan was repeated and showed stable focus in the left glenohumeral region, but HPO had resolved. No findings were highly suspicious for metastatic disease to the bone.
Since its original description by Hippocrates in the fifth century BC, the strong association of digital clubbing and HPO with serious disease has been a clinical enigma. There is both indirect and direct evidence that a substantial number of megakaryocytes arrest in the pulmonary capillary bed and release platelets at this site. 4 Thanks to arteriovenous shunts (either in the heart or in the lungs) these circulating megakaryocytes or their fragments reach the fingertips in the axial vascular stream, releasing factors such as vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF), which induce the stromal and vascular changes present in HPO. 5 This explains why there were no signs of HPO recurrence when our patient developed brain metastases, as HPO requires intrapulmonary arteriovenous shunting.
As anti-VEGF monoclonal antibodies (eg, bevacizumab) and VEGF pathway inhibitors (several drugs in different phases of clinical trials) become more frequently used in the clinical practice of various cancers, it is likely that we will learn more about the pathogenesis of HPO in the near future.
Long-Term Survival After Glioblastoma Multiforme
To the Editor: Glioblastoma multiforme (GBM) is the most aggressive of primary brain tumors with a median survival of approximately 12 months; fewer than 25% of patients survive up to 2 years and fewer than 10% up to 5 years. 1 We report a very rare case of a patient who survived for 12 years following diagnosis of GBM. The patient, a 65-year-old African-American woman, was brought to the emergency room in October 2007 because "she was not acting right." Her speech was very low and incomprehensible. She looked weak, somnolent, and slightly more lethargic than her usual self. Past medical history was remarkable for GBM 12 years previously. In April 1995, a 3 cm ring-enhancing lesion was detected by magnetic resonance imaging (MRI) in her right temporal lobe. Pathology showed GBM with sarcomatoid features. The patient was treated with surgery, radiation (6000 rads) and chemotherapy with BCNU (Carmustine). She also had intra-arterial chemotherapy given at the tumor site using femoral catheterization. She was then lost to followup until recently.
MRI with and without contrast showed a focal 4.6 ϫ 3.5 ϫ 3.0 cm left frontal lobe subcortical and deep white matter-enhancing mass with central septation and internal fluid. Vasogenic edema surrounding the left frontal lobe was extended into the anterior left corona radiata and the anterior limb of the left internal and external capsule. There was left to right subfalcine herniation with bifrontal lateral hemispheric mass effect and effacement. These findings could be due to a new tumor or cerebral necrosis. Unfortunately, the patient and her family decided not to do a biopsy. She was then lost to follow-up. Hospital records show that on April 4 th 2008 she was brought to the ER because she fell from a chair which meant the patient was still alive 13 years after the initial GB diagnosis. Despite extensive clinical trials, individual prediction of clinical outcome has remained an elusive goal. Reports of living more than 10 years after GBM are very rare. Patient survival depends on a variety of clinical and biologic parameters including tumor size and location, younger age (Ͻ40 years), functional status at presentation (Karnofsky score), aggressive surgical and multimodal treatment including radiotherapy and chemotherapy (temozolomide), 2 histologic indicators (lower mitotic index), and genetic markers O-6-methylguanine-DNA methyl transferase (MGMT) gene silencing. 3 A potential problem in these patients is cognitive decline after treatment. In one study, long-term survival was frequently accompanied by severe treatment-induced dementia. 4 However, in another study, attention, construction, and arithmetic abilities were impaired, but the level of functioning, Karnofsky score, and overall quality of life were stable. 5 In conclusion, GBM patients can, in rare cases, survive over 10 years; however, the risk of residual functional difficulties is significant.
Hydrocortisone in
To the Editor: The use of glucocorticoids in severe sepsis has had its fair share of controversy. In the 1960s, studies in animal models suggested that steroids might have survival benefits in sepsis and paved the way for trials with large doses.
1 By the mid-1990s, metaanalysis disproved the efficacy of large doses of steroids with secondary infections due to the attendant immunosuppression becoming a concern.
2 A belief emerged around this time that the loss of response of the adrenal gland to corticotropin injection in septic patients was etiologically related to the hemodynamic instability of sepsis and mortality. 3 As a result, the concept of adrenal replacement therapy with low-dose corticosteroids was born. The belief that nonresponders were those who would benefit from corticosteroid therapy was reinforced by a meta-analysis by Minneci et al 4 supporting lowdose hydrocortisone in divided doses for patients on vasopressor support and in corticotropin-negative responders, provided the steroids were administered for a minimum of 5 days followed by a tapering period of 5 to 7 days.
The new publication of a multicenter, randomized, controlled and double-blinded study by Sprung et al 5 at the beginning of 2008 is the latest in a growing list of dissenters. This study concluded that hydrocortisone did not demonstrate survival improvement in severe sepsis when compared with placebo. The study also failed to show proof of shock reversal either in the overall patients or in the corticotropinnonresponding subgroup, although it hastened the reversal of shock in those in whom shock was reversed.
Armed with mounting statistics on a specific treatment for a particular pathology in the same species, how could we have failed to reach consensus for so long? Regardless of the era of publication, it has to be assumed that clinical investigators in this subject gave it their best efforts and meant well for their patients. Yet questions remain unanswered. We surmise that the missing link in this controversy is bias. Previous publications have probably been tainted with selection bias, while publication bias misled meta-analyses based on those studies.
The pharmaceutical industry has not been particularly benevolent in funding research and, therefore, one has to wonder whether the financial influence it has in clinical trials may not have contributed to this clinical perplexity. Now that we are tending toward accepting the null hypothesis, future trials need to have more stringency to prove that hydrocortisone impacts beneficially in sepsis.
Robert A 34-year-old woman who had iron deficiency anemia was admitted to our gastroenterology department for colonoscopic examination. Colonoscopy was completely normal. Seven hours after the colonoscopy, she developed bloody diarrhea and mild abdominal pain. An abdominal examination was normal other than lower abdominal tenderness. Hemoglobin did not decrease. Stool microscopy showed erythrocytes, and a culture revealed normal flora. Plain abdominal radiography and abdominal ultrasonography were both normal. A repeat colonoscopy was performed and showed patchy hemorrhagic, edematous, and thickened mucosa, with superficial ulceration extending from the proximal rectum to the splenic flexure. Histologic analysis was compatible with ischemic colitis. Tests for antinuclear antibodies, anti-DNA antibodies and antimitochondrial antibodies were negative. Over the next two days, the patient's abdominal pain and bloody stools improved gradually. On the fifth day, colonoscopy revealed normal colon mucosa. She was free of complaints at her four month follow-up visit.
Ischemic colitis presents as a spectrum of injury from transient ischemia involving the mucosa and submucosa to acute fulminant necrosis that may progress to death. 2 Although there is a variety of causes, two main mechanisms may lead to bowel ischemia: reduced large bowel perfusion because of low cardiac output, or occlusive disease of the bowel vascular system. 1,2 However, the actual cause for the ischemia may not always be identified.
1 Ischemic colitis very rarely occurs as a result of colonoscopic examination. Underlying connective tissue disorders are often the predisposing factors in those cases. 3, 4 Cremers et al 5 reported colonoscopy-induced ischemic colitis in a patient without an underlying predisposing factor. Our patient developed ischemic mucosal injury secondary to colonoscopy. She had no risk factors, including connective tissue disorders, or drug intake, including oral contraceptives. She also did not have intraprocedural hypotension or a history of gastrointestinal or systemic disease.
Three mechanisms may have contributed to the colonoscopy-induced ischemic colitis in our present case. First, overdistention of the large bowel with air might have reduced colonic blood flow and thus caused a shunting of blood from the mucosa to the serosa, consequently producing colonic ischemia. 4 Second, the mechanical effect of the colonoscope body on the colon wall may have led to diminished mucosal blood flow. Third, transient torsion of the colonic vascular system resulting from exaggerated pulling back and shortening might have reduced the blood flow.
The prognosis in colonoscopy-induced ischemic colitis usually has been reported as good, [3] [4] [5] but ischemia with necrosis may extend into the deep layers of the bowel wall and impair the colonic barrier against microorganisms. Thereby, it may increase mortality and morbidity, particularly in patients with comorbid diseases, immunodepressive disorders, or compensated mesenteric ischemia.
